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Following Salmonella invasion, intestinal epithelial cells release a distinct array of proinﬂammatory cytokines. Interleukin (IL)-6
produced by enterocytes may have anti-inﬂammatory and cell-protective eﬀects, and may counteract some of the injurious eﬀects
of sepsis and endotoxemia. Recent studies in a variety of rodent models of experimental colitis by using PJ-34, a potent poly
(ADP-ribose) polymerase-1 (PARP-1) inhibitor, support the concept that the marked beneﬁcial eﬀect of PJ-34 can be exploited
to treat human inﬂammatory diseases. The present study was to investigate the eﬀect of PJ-34 on Salmonella-induced enterocyte
IL-6 production and its mechanisms. We found that PJ-34 enhanced Salmonella-induced IL-6 production in Caco-2 cells, either
secretedproteinormRNAexpression.PJ-34treatmentenhancedtheactivityofNF-κBinSalmonella-infectedCaco-2cells.Besides,
the involvement of PJ-34 in up-regulating IL-6 production in S. typhimurium-infected Caco-2 cells might be also through the
ERK but not p38 MAPK, JNK or PI3K/Akt pathways, as demonstrated by Western blot of phosphorylated ERK, p38, JNK and Akt
proteins. It suggests that PJ-34 may exert its protective eﬀect on intestinal epithelial cells against invasive Salmonella infection by
up-regulating IL-6 production through ERK and NF-κB but not P38 MAPK, JNK or PI3K/Akt signal pathways.
Copyright © 2009 Fu-Chen Huang. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1.Background
Epithelial cells have been recognized as playing an impor-
tant role in mucosal immunity through the expression
of proinﬂammatory cytokines in response to microbial
injury [1]. Among cytokines produced in the intestinal
mucosa during sepsis and endotoxemia, interleukin (IL)-6
is particularly important because of its multiple signiﬁcant
biological eﬀects [2]. Although commonly considered a
proinﬂammatory cytokine [3], there is also evidence that
IL-6 has important antiinﬂammatory properties and may
exert protective eﬀects in various tissues [4–6]. IL-6 plays an
essential role in the intestinal barrier in L. monocytogenes-
infected human intestinal epithelial cells [7, 8]. Because of
the multiple biological eﬀects of IL-6, a better understanding
of the molecular regulation of enterocyte IL-6 production
and methods to modulate IL-6 production in intestinal
mucosa in infected enterocytes may have important clinical
implications.
Over the last decade, a multitude of studies have veriﬁed
the role of PARP-1 activation in a wide range of pathophys-
iologic conditions, such as arthritis, asthma, inﬂammatory
bowel disease, lung inﬂammation, multiple organ failure,
and septic shock [9]. The marked beneﬁcial eﬀect of PARP
inhibitors in these animal models of various diseases also
suggests that PARP inhibitors can be exploited to treat
human inﬂammatory diseases.
T h er e c e n ts t u d i e si nav a r i e t yo fr o d e n tm o d e l so f
experimental colitis support the role of PARP-1 activation
in the pathogenesis of the disease [10–14]. PJ-34, a novel
and highly potent (the in vitro IC50 is 10000 times lower
thanthatoftheprototypicalcompound3-aminobenzamide)
PARP-1 inhibitor, is suitable for mechanistic investigations
into the regulatory roles of PARP [15]. Furthermore, PJ-
34 treatment improved survival in septic shock induced by
bacterial peritonitis in pigs [16]. However, the role of PARP
in the pathogenesis of Salmonella enteritis and the eﬀect
of the PARP-1 inhibitor PJ-34 and genetic knock down of2 Mediators of Inﬂammation
PARP-1 siRNA on the inﬂammatory response of enterocytes
to Salmonella infection are not known, prompting us to
investigate the role of PJ-34 in Salmonella-induced intestinal
inﬂammation and its mechanisms.
2. Aim
In this study, we aimed to examine the eﬀect of PJ-34 on
Salmonella-induced IL-6 production in Caco-2 cells in vitro
and the intracellular signaling pathways regulating the eﬀect.
3.MaterialsandMethods
3.1.Reagents. PJ-34waspurchasedfromInotekCorporation
(Beverly,MA)andstocksolutionsmadeindimethylsulfoxide
(DMSO). The inhibitor was added to cells at the speciﬁed
concentrations about 30–60 minutes before infection. Stan-
dard laboratory reagents were from Sigma (St. Louis, MO).
3.2. Bacterial Strains. The wild-type S. typhimurium strain
SL1344 has been described previously [17, 18]. Bacteria were
grown overnight in static cultures with minimal aeration
in Luria-Bertani (LB) medium. The bacteria were collected
by centrifugation at 14000g for 5 minutes, washed with
sterile phosphate-buﬀered saline (PBS), and resuspended in
tissue culture medium without antibiotics at a density of
4 × 109/ml. Twenty-ﬁve μl aliquots of this suspension (108
bacteria) were used to infect the cells.
3.3. Cell Culture and Infection. Caco-2 cells (ATCC,
Rockville, MD), a transformed human colonic epithelial
cell line, were grown in Dulbecco modiﬁed Eagle medium
(DMEM) supplemented with 10% heat-inactivated fetal
calf serum, 100units/ml penicillin, 100μg/ml streptomycin
sulfate,and20mMHEPES(Sigma)ina5%CO2 atmosphere
at 37◦C. Passage 10–30 was used for all experiments. For
some infection experiments, cells were seeded in 12-well
tissue culture plates (4cm2/well; BD Biosciences) and used
at 60%–80% conﬂuence.
3.4. Cell Fractionation. Cytosolic, nuclear, and membranous
extracts from uninfected, infected, or PJ-34-treated Caco-
2 cells were prepared by the method of Wang et al. [19]
with slight modiﬁcations. Cells were washed twice with ice-
cold phosphate-buﬀered saline, lysed in buﬀer A (10mM
Hepes-KOH, pH 7.8, 10mM KCl, 2mM MgCl2,0 . 1 m M
EDTA, 0.1mM EGTA, 0.7% Nonidet P-40) with protease
and phosphatase inhibitors for 30minutes on ice, vortexed
vigorously for 15s, and centrifuged at 3000 × ga t4 ◦Cf o r
10 minutes (the supernatants are the cytosolic fractions).
The pelleted nuclei and membrane were resuspended in
buﬀer B (40mM Hepes-KOH, pH 7.8, 350mM NaCl, 2mM
MgCl2, 1mM EDTA, 0.2 mM EGTA, 20% glycerol, 1%
Nonidet P-40) with protease and phosphatase inhibitors for
60 minutes on ice, mixed vigorously for 10 s at 15, 30 and
45 minutes, and centrifuged at 15,000 ×ga t4 ◦Cf o r3 0
minutes. Supernatants containing the nuclear proteins were
storedat −80◦C.Thepelletedmembranewasresuspendedin
lysisbuﬀerwithproteaseandphosphataseinhibitors.Protein
concentrations in cell fractions were determined using a Bio-
Rad assay kit.
3.5. Cytokine Assay. Caco-2 monolayers were infected (api-
cally, in the case of the polarized monolayers) in triplicate
for 1 hour at 37◦C. The medium was aspirated at the end
of the infection period, the cells were washed twice with
sterile PBS, and medium containing gentamicin at 100μg/ml
was added. After incubating for 5 hours at 37◦C, the
supernatant medium was collected and IL-6 concentrations
were determined by enzyme-linked immunosorbent assay
(ELISA) as described below. The cells were washed with
PBS and lysed with 0.2ml of 1% Triton X-100. An aliquot
of the lysate was used to determine protein concentration
by the DC protein assay (Bio-Rad, Hercules, CA) follow-
ing instructions provided by the manufacturer. The IL-6
concentration was assessed using an OptEIA human IL-
6 enzyme-linked immunosorbent assay (ELISA) set (BD
Biosciences) as described by the manufacturer. To allow
comparison between multiple experiments, the amount of
IL-6 produced was normalized to the protein content of
the cell monolayer. Because of variations in baseline IL-6
production, the results were expressed as “fold increase”,
representing the normalized IL-6 produced by infected
monolayers divided by the normalized IL-6 produced by
control, uninfected monolayers.
3.6. RNA Isolation and cDNA Synthesis. Total RNA was
prepared from control or infected cells with the Trizol
reagent (Invitrogen Corporation, Carlsbad, CA), following
the manufacturer’s directions. The RNA was reversetran-
scribed with random hexamers using the GeneAmp kit
(Roche, Nutley, NJ) as described in detail earlier [17, 18].
3.7.Real-TimeReverseTranscriptionPCR. Real-timereverse-
transcription PCR analyses were performed in a ﬂuores-
cence temperature cycler (LightCycler; Roche Diagnostics)
as described previously [20]. This technique continuously
monitors the cycle-by-cycle accumulation of ﬂuorescently-
labeled PCR product. Brieﬂy, cDNA corresponding to 10ng
o fR N As e r v e da sat e m p l a t ei na1 0μl reaction containing
4mMMgCl 2,0 . 5μMo fe a c hp r i m e r ,a n d1 × LightCycler-
FastStart DNA Master SYBR Green I mix (Roche Diagnos-
tics). Samples were loaded into capillary tubes and incubated
in the ﬂuorescence thermocycler (Light-Cycler) for an initial
denaturation at 95◦C for 10 minutes followed by 45 cycles,
each cycle consisting of 95◦C for 10s, 58◦Cf o r5s ,a n d7 2 ◦C
f o r2 0s .A tt h ee n do fe a c hr u n ,m e l t i n gc u r v ep r o ﬁ l e sw e r e
produced by cooling the sample to 65◦C for 15s and then
heating slowly at 0.20◦C/s up to 95◦Cw i t hc o n t i n u o u sm e a -
surement of ﬂuorescence to conﬁrm ampliﬁcation of speciﬁc
transcripts. Cycle-to-cycle ﬂuorescence emission readings
were monitored and analyzed using LightCycler software
(Roche Diagnostics). The speciﬁcity of the ampliﬁcation
products was further veriﬁed by subjecting the ampliﬁcation
products to electrophoresis on a 2% agarose gel. The
fragmentswerevisualizedbyethidiumbromidestaining,andMediators of Inﬂammation 3
the speciﬁcity of PCR products was veriﬁed by sequencing of
representative samples. The following primers were used: IL-
6, 5 - ATG AAC TCC TTC TCC ACA AGC GC-3  (f o r w a r d
primer) and 5 -G AAG AGC CCT CAG GCT GGACTG-
3  (reverse primer, 628bp); and glyceraldehyde-3-phosphate
dehydrogenase, 5 -CCAGCCGAGCCACATCGCTC-3  (for-
ward primer) and 5 -ATGAGCCCCAGCCTTCTCCAT-3 .
Standard curves were obtained for each primer set with
serialdilutionsofcDNA.Allquantiﬁcationswerenormalized
to the housekeeping gene glyceraldehyde-3-phosphate dehy-
drogenase. Relative expression was given as a ratio between
target gene expression and glyceraldehyde-3-phosphate
dehydrogenase expression.
3.8. Western Blotting. Equal amounts of total protein were
separated by SDS-PAGE and then transferred to nitrocellu-
lose membranes by semidry blotting as previously described
[17, 18]. After blocking the membranes with 5% nonfat dry
milk, they were probed with antibodies to phosphorylated
Akt (Cell Signaling, Beverly, MA), phosphorylated IκB( N e w
E n g l a n dB i o L a b s ,B e v e r l y ,M A ) ,p 6 5N F - κB or phosphory-
lated ERK (Santa Cruz Biotechnology, Santa Cruz, CA), and
phosphorylated JNK or p38 (New England BioLabs, Beverly,
MA). The membrane was continuously incubated with
appropriate secondary antibodies coupled to horseradish
peroxidase and developed in the ECL Western detection
reagents (Amersham–Pharmacia Biotech, Piscataway, NJ,
USA). Appropriate exposures to X-ray ﬁlm were made, and
theﬁltersthenstrippedandreprobedwithantibodiestototal
Akt (Cell Signaling, Beverly, MA), total ERK, p38, IκB, β-
actin, LaminA/C, or E-cadherin (Santa Cruz Biotechnology,
Santa Cruz, CA) as appropriate.
3.9. Statistical Analysis. All experiments were carried out at
least twice with similar results. Statistical signiﬁcance was
determined using Student’s t-test.
4. Results
4.1. PJ-34, PARP-1 Inhibitor, Potentiates Salmonella-Induced
IL-6 Production. In Figure 1, we found that enhancement of
theIL-6,eitherinproteinsecretionormRNAexpression,was
increased as higher concentration of PJ-34 was applied (sta-
tistically signiﬁcant after 20μM PJ-34). Then, we proceeded
to study the mechanisms of the eﬀect of PJ-34 on IL-6.
4.2. PJ-34 Enhances and Prolongs the Activation of NF-κB
by Increasing IκB-α Degradation and Nuclear Translocation
of NF-κB. To further elucidate the mechanism by which
PJ-34, PARP-1 inhibitor, increased Salmonella-induced IL-
6 production in intestinal epithelial cells, we examined the
intracellular signaling pathways that have been implicated in
expression of the cytokine. The transcriptional regulation of
the IL-6 gene is complex and involves diﬀerent transcription
factors [21]. Transcription factor NF-κB is a key transcrip-
tion factor in the regulation of cytokines and chemokines,
including IL-6 gene expression [22]. Activation of the NF-
κB pathway, as well as the mitogen-activated protein kinases
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Figure 1: (a) Eﬀe c to fP J - 3 4o nSalmonella-induced IL-6 protein
secretion. Caco-2 cells were left untreated (control), or treated
with 5, 10, 20, 40, or 80μM PJ-34 (5, 10, 20, 40, 80PJ), or with
a volume of DMSO (D) equivalent to the highest concentration
of PJ-34. They were then uninfected (control and PJ only) or
infected with the wild-type S. typhimurium strain SL1344 for 1
hour. Supernatant was analyzed by ELISA 6 hours later for IL-6.
The amount of IL-6 produced is shown as the fold increase over
uninfected, control cells. The results are representative of the results
of two similar experiments. The data are the means ± standard
deviations for three determinations. ∗P<. 05. (b) Eﬀe c to fP J - 3 4o n
Salmonella-induced IL-6 mRNA. Caco-2 cells were left untreated,
or treated with 5, 10, 20, 40, or 80μM PJ-34. They were then
uninfected or infected with the wild-type S. Typhimurium strain
SL1344 for 1 hour. Total RNA was prepared 3 hours later and
analyzed by real-time quantitative PCR to estimate amounts of IL-6
transcript. The amount of IL-6 mRNA produced, normalized to the
corresponding amount of GAPDH transcript, is shown as the fold
increaseoveruninfected,controlcells.Theresultsarerepresentative
of the results of two similar experiments. The data are the means ±
standard deviations for three determinations. ∗P<. 05.
(MAPK); extracellular growth factor-regulated kinase (ERK)
and p38, has all been shown to be involved in Salmonella-
induced cytokines and chemokines production [17, 23, 24].
To determine the involvement of these signals in the eﬀect
of PJ-34 on Salmonella-infected intestinal epithelial cells,
Caco-2 cells were left untreated, or treated with 40μMP J -
34, and then infected with the wild-type Salmonella strain
SL1344. Activation of the NF-κB pathway was assessed by
examining nuclear translocation of NF-κB and degradation
of the inhibitor protein IκB-α. As shown in Figure 2(a),
Salmonella infection resulted in degradation of IκB-α and
nucleartranslocationofNF-κB.PJ-34enhancesandprolongs
the activation of NF-κB by increasing IκB-α degradation and
nuclear translocation of NF-κB( Figure 2(b)), resulting in
subsequent upregulation of IL-6 gene transcription.4 Mediators of Inﬂammation
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Figure 2: Eﬀect of PJ-34 on Salmonella-induced activation of NF-κB.N F - κB is a central regulator of the intestinal epithelial cell innate
immune response induced by infection with enteroinvasive bacteria. The Western blots illustrate (a) the expression of Iκ-Bα proteins in
cytosolic extracts of Caco-2 cells exposed to wild-type S. Typhimurium strain SL1344 in the absence or presence of PJ-34. Actin works as
a normalization of nuclear protein and (b) the expression of p65 NF-kB proteins in nuclear extracts of Caco-2 cells exposed to wild-type
S. Typhimurium strain SL1344 in the absence or presence of PJ-34. Actin and LaminA/C work as a normalization of cytosolic and nuclear
protein, respectively. The results shown are representative of 3 separate experiments.
4.3. PJ-34 Enhanced ERK Phosphorylation in Salmonella-
Infected Intestinal Epithelial Cells but Did Not Alter the JNK
or p38-MAPK Phosphorylation. We also examined activation
of MAPKs (ERK, JNK, and p38 kinases) (Figure 3), using
antibodies speciﬁc to either the phosphorylated (activated)
or total forms of these proteins. While inhibition of PARP
with PJ-34 had no eﬀect on Salmonella-dependent phospho-
rylation of the p38 kinase and JNK, it had a clear and repro-
ducible enhancing eﬀect on activation of the ERK kinase.
These ﬁndings suggest that MAPK pathways are involved
in the regulatory eﬀect of PJ-34 on Salmonella-induced IL-
6 production in intestinal epithelial cells. However, they
diﬀerentially regulate the cell responses.
4.4. PJ-34 Has No Eﬀe c to nt h eM e m b r a n o u sR e c r u i t m e n t
and Activation of AKT in Salmonella-Infected Caco-2 Cells.
NF-κB is a key transcription factor in the regulation of
proinﬂammatory cytokines and chemokines. Besides, an
intimate relationship between that NF-κB and PARP-1 is
demonstrated by the multiple lines of evidence showing
that the synthesis of poly(ADP-ribose) promotes NF-κB
transactivation and inhibition of PARP-1 can attenuate this
activationandsubsequentcytokineexpression.Somereports
have also demonstrated that PARP inhibitors induced the
phosphorylationandactivationofAktinlipopolysaccharide-
treated mice or cultured cells during oxidative stress, raising
the protective eﬀect of PARP inhibition mediated through
the PI3K-kinase/Akt pathway. In our previous studies, we
demonstratedNF-κBandPI3K/Aktpathwaysplayimportant
roles in the pathogenesis of Salmonella enteritis [17, 18].
However, we found inhibition of PARP-1 with PJ-34 had
no eﬀect on Salmonella-induced phosphorylation of Akt
(Figure 4).
5. Discussion
Our study gave ﬁrst insight into the regulatory eﬀect on the
inﬂammatory responses by a novel PARP-1 inhibitor PJ-34
in Salmonella-infected intestinal epithelial Caco-2 cells. In
this study, we found that wild-type S. typhimurium induced
IL-6 production in Caco-2 cells, whereas PJ-34 enhanced IL-
6 expression, either secreted IL-6 or IL-6 mRNA. Although
commonlyconsideredaproinﬂammatorycytokine[3],there
is also evidence that IL-6 has important antiinﬂammatory
properties and may exert protective eﬀects in various tissues
[4–6]. The studies from Hasselgren et al. suggest that IL-
6 produced by enterocytes may have antiinﬂammatory and
cell-protective eﬀects and that increased IL-6 levels in gut
mucosamaycounteractsomeoftheinjuriouseﬀectsofsepsis
and endotoxemia [25, 26]. Intense inﬂammatory response
induced by Salmonella infection results in destruction of
the epithelial layer of the intestinal mucosa that may lead
to translocation of bacteria and absorption of endotoxins
into the circulation [27, 28]. Consequently, translocation of
bacteria and absorption of endotoxins may have profound
systemic eﬀects and may result in bacteremia as well as endo-
toxemia. However, IL-6 has been described to be a mediator
of epithelial barrier protection [29] and endogenous IL-6
plays an essential, nonredundant role in limiting intestinal
injury and cell death [30]. Probiotic bacterium L. paracasei
may exert some of their beneﬁcial eﬀects by enhancing IL-
6 production in enterocytes subjected to an inﬂammatory
stimulus [31].
In our study, PJ-34 upregulated the Salmonella-induced
IL-6 production. That might explain the marked beneﬁcial
eﬀect of PJ-34 in various models of local inﬂammation in
rodents, in which the levels of IL-6 were not measured
[32].PJ-34mayprovidetheantiinﬂammatoryandprotectiveMediators of Inﬂammation 5
40
55
55
40
55
40
40
33
43
C5   15  30  60  5  15  30  60 
pERK: 42KDa
ERK: 42KDa
Infection PJ-34
pP38: 42KDa
P38: 38KDa
P-JNK: 43/65KDa
Figure 3: Eﬀect of PJ-34 on Salmonella-activated intracellular signals. Caco-2 cells were left untreated, or treated with 40μM PJ-34, and then
infected with wild-type S. Typhimurium strain SL1344 for the times indicated. Activations of the ERK, JNK, and p38 were analyzed in whole
cell protein by immunoblotting with antibodies to phosphorylated (p) ERK, JNK, and p38 and total ERK and p38. The activation of ERK
was enhanced by PJ-34 but not the JNK and p38. The results shown are representative of 3 separate experiments.
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Figure4:EﬀectofPJ-34onSalmonella-activatedintracellularsignals.
Caco-2 cells were left untreated, or treated with 40μM PJ-34, and
then infected with wild-type S. Typhimurium strain SL1344 for the
times indicated. Activation of the AKT pathway was analyzed in
cell fraction (membrane part) by immunoblotting with antibodies
to phosphorylated (p) AKT and total AKT. E-cadherin works
as a normalization of membranous protein. The results shown
are representative of 3 separate experiments. The activation and
recruitment of Akt were not signiﬁcantly suppressed by PJ-34.
eﬀects on intestinal epithelial cells to counteract the invasion
and injurious eﬀects of Salmonella endotoxemia through the
upregulation of enterocyte IL-6 production. To the best of
o u rk n o w l e d g e ,u pt on o w ,n or e p o r th a sd e m o n s t r a t e dt h a t
PJ-34 upregulated Salmonella-induced IL-6 expression in
intestinal epithelial cells.
It has been previously reported that genetic deﬁciency
or pharmacological inhibition of PARP-1 confers beneﬁcial
eﬀects in experimental models of colitis [10–14, 32, 33].
Blockade of PARP inhibits intercellular adhesion molecule
1 (ICAM-1) or cyclooxygenase-2 expression [13, 33], neu-
trophil recruitment [13, 14, 33], oxidant generation, and
mucosal injury in murine colitis. However, one (rare) report
has demonstrated the eﬀect of PJ-34 on Il-6 production [34].
Analysis of local expression of the IL-6 in skeletal muscle
after ischemia and 48h of reperfusion showed signiﬁcantly
higher levels in the PJ-34 treated group when compared with
saline. The authors suggested that not all cytokine activity
during reperfusion is deleterious. It might provide protective
or antiinﬂammatory eﬀects.
The transcriptional regulation of the IL-6 gene is
complex and involves diﬀerent transcription factors [21].
Transcription factor NF-κB is a central regulator of IL-
6 gene expression [22]. Activation of the NF-κBp a t h w a y ,
as well as the mitogen-activated protein kinases (MAPKs):
extracellular growth factor-regulated kinase (ERK) and p38,
has been shown to be involved in Salmonella-induced
cytokines and chemokines production [17, 22, 23]. Besides,
the diversity of signal pathways involved in the protective
eﬀect of PARP inhibitors depends on the experiment models
and inhibitors used. Most studies [10–14] have shown
reduced activation of transcription factors NF-κB and AP-1,
whileveryfewstudieshaveshownincreasedphosphorylation
of MAPK and PI3K/Akt pathways except JNK. L-2286, a
novel PARP inhibitor, facilitated the ischemia-reperfusion-
induced activation of Akt, ERK, and p38-MAPK in both
isolated hearts and in vivo cardiac injury [35].
To further elucidate the mechanism by which PJ-34
upregulated IL-6 production, we examined various signaling
pathways that have been implicated in expression of the
cytokine. While inhibition of PARP-1 with PJ-34 had no
eﬀect on Salmonella-induced phosphorylation of the p38
kinase, JNK, or Akt, it had a clear and reproducible
enhancing eﬀect on activation of the ERK kinase and nuclear
translocation of NF-κB. These ﬁndings are in contrast with
previous reports in A549 lung epithelial cells [36]o rW R L -
68 human liver cells [37]. They found that PJ-34 suppressed
NF-κB activation but not AP-1 in cytokine-stimulated A549
cells and had no eﬀect on the expression of most chemokines
[36]. They also showed that PJ-34 had no eﬀect on phos-
phorylation of all MAPKs. In WRL-68 cells transfected with
PARP siRNA or pharmacologically inhibited by PJ-34, the
phosphorylation of Akt (Ser473) increased during oxidative
stress compared with wild type. Nevertheless, in accordance
with our results, Kameoka et al. [38] demonstrated an
inversecorrelationbetweenPARPandNF-κBactivities.They
showed that Cl-3527 cells with the lowest PARP content
expressed 35-fold greater activity of NF-κB than wild-type
L1210 cells. However, a discrepancy seems to exist with Cl-
3527 and the PARP-1-gene disrupted cells [39, 40], which6 Mediators of Inﬂammation
showed markedly suppressed NF-κB-dependent signaling.
These authors explained that the discrepancy may be due to
the diﬀerence in the residual poly(ADP-ribosylating) activity
in these mutants. It suggested that transcription factors and
signal pathways varied between diﬀerent cell types and may
also vary within the same cell depending on stimulus [41].
Our results suggest that might also modulate a diverse
array of signaling cascades beside gene expression. To our
knowledge, this is the ﬁrst in vitro report, which attributes
ac r i t i c a lr o l et oN F - κB and ERK in the Salmonella-induced
upregulation of IL-6 in Caco-2 cells, conferred by PARP-1
inhibitor PJ-34.
6. Conclusions
In conclusion, the present study provides the ﬁrst evidence
that PJ-34 may enhance IL-6 production in enterocytes
subjected to Salmonella infection and that the eﬀect of
PJ-34 is, at least in part, through NF-κB and ERK signal
pathways. Because other studies have shown that IL-6 has
antiinﬂammatory and protective eﬀects in the intestinal
mucosa, the present results oﬀer a novel mechanism by
which PJ-34 may exert some of its beneﬁcial eﬀects, although
additional in vivo experiments will be needed to deﬁne
the role of IL-6 in cell-protective eﬀects provided by PJ-34
treatment.
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